Some of the prominent tumor antigens that have contributed greatly to the development of therapeutic vaccines, particularly in HNSCC, are the melanoma antigen-encoding gene (MAGE) (CTA), HPV-E6, E7 (oncoviral), Epstein–Barr virus (EBV)-related latent membrane protein (LMP)-2 (oncoviral), MUC-1, Wilm’s tumor (WT)-1, survivin, carcinoembryonic antigen (CEA) (overexpressed and SHA), and epidermal growth factor receptor(EGFR)-vIII (neoantigen) [32]. This evidence concerns the gene PSMB9 and neoplasm.